Gonadotrophin-surge-attenuating factor (GnSAF) is a putative nonsteroidal ovarian factor that is produced by FSH 
Introduction
Several studies in vivo have provided evidence that the ovaries of superovulated women produce a nonsteroidal substance, named gonadotrophin-surge-attenuating factor (GnSAF) , that attenuates the endogenous LH surge by reducing the response of LH to LHRH (Messinis and Templeton, 1989 , 1991a . In these studies, the change in the response of LH to LHRH as a bioassay for GnSAF in vivo has shown that this factor is active during the follicular and the luteal phase of the human menstrual cycle Messinis et al, 1993a) . Although GnSAF has not yet been purified, studies in vitro have shown that GnSAF activity is present in steroidfree human follicular fluid and is different from that of inhibin (Busbridge et al, 1990; Fowler et al, 1990; Knight et al, 1990 ).
It has been demonstrated that during the early follicular phase of the human menstrual cycle FSH is a potent stimulator of GnSAF production (Messinis et al, 1991 (Messinis et al, , 1993b in previous studies (Messinis et al, 1991 (Messinis et al, , 1993a (Messinis et al, , 1993b Day of cycle Basal LH and oestradiol concentrations before the treatment were similar in the two cycles (Fig. 3) (Messinis et al, 1991 (Messinis et al, , 1993b (Lasley et al, 1975; Wang et al, 1976) . The self-priming effect was also evident in the present study, even though in this case LHRH was injected every 4 h. In superovulated cycles, in which FSH is given on a daily basis, GnSAF attenuates the self-priming action of LHRH on the pituitary (Messinis and Templeton, 1991a Information regarding the effects of these substances on gonadotrophin secretion is mainly derived from studies in vitro; their physiological importance is therefore obscure (Burger, 1992 (Busbridge et al, 1990; Fowler et al, 1990; Knight et al, 1990) . In addition, preliminary data have shown that GnSAF has a molecular mass in the range of 10-30 kDa (Fowler et al, 1992 (Hoff et al, 1977) . This is based on experimental data showing that exogenous administration of oestrogen to hypogonadal women results in a reduction or no alteration in the pituitary sensitivity to LHRH and an increase in the pituitary reserve (Lasley et al, 1975; Quyyumi et al, 1993) . However, when the serum concentration of oestradiol increases rapidly during the early follicular phase of the cycle after exogenous administration, it enhances pituitary sensitivity to LHRH (Lasley et al, 1975 (Messinis and Templeton, 1991b) 
